On April 11, a cold chain logistics delivery vehicle left Beijing Tianzhu Comprehensive Bonded Area and arrived at Beijing Children's Hospital in a one-stop manner. Vosolide, the world's first rare drug for treating children with achondroplasia, which has been listed overseas, was transported from the bonded warehouse to the hospital pharmacy, and finally successfully delivered to a pair of parents of twin patients from Shandong. "This is really great. The children can get the bonded drugs in a one-stop way after seeing a doctor here. For our patients, it not only gets the authoritative diagnosis and treatment, but also saves the time cost and economic cost." The patient's parents said.

It is understood that children's achondroplasia, also known as fetal chondrodystrophy, chondrodystrophy dwarfs, is a congenital developmental anomaly due to defects of endochondral ossification, a rare disease in children, with an incidence of about 1/25000, and about 10000 children in China. "At present, there are more than 7000 rare diseases in the world, 70% of which are hereditary rare diseases that affect patients from childhood. The treatment of children's rare diseases is of great significance, and should be found, diagnosed and treated early. As a national children's medical center, Beijing Children's Hospital has actively responded to the policy call of the State Council, created the shortest time record for the import approval and clinical application of domestic unlisted drugs, effectively introduced voxolide, a drug for children's chondrosis, into the hospital, highlighting the core concept of "everything for children", and will continue to play its own advantages in the future, Let the policy benefit more children in China. " Ni Xin, president of Beijing Children's Hospital, said.

The person in charge of the trade of Shanghai Pharmaceutical Science Park, an enterprise in the airport economic zone of the Capital Airport, said that this drug has been used in more than 70 countries and regions around the world, and has been used since several months of age, with obvious therapeutic effects. The existing foreign clinical research results show that the growth rate of patients receiving treatment is continuously higher than the baseline level of patients, and is significantly higher than the expected annual growth rate of untreated patients. In addition, no acceleration of bone age has been observed, showing a good therapeutic effect. "As a pharmaceutical trade enterprise in the airport economic zone of the Capital Airport, we are very willing to give play to our own advantages, devote ourselves to the work of rare disease drug security, and participate in the construction of the pilot area for rare disease drug security."

"This drug security has adopted the mode of bonded stock, which should be said to have significantly saved the time for drug negotiation and purchase and import. The time saved is conservatively estimated to be more than 60 days, greatly improving the accessibility of drugs. Next, the policy of the pilot area for rare disease drug security is expected to be significantly optimized after it is officially implemented." The head of the airport economic zone management committee of the Capital Airport said.

It is reported that at the end of 2023, the State Council approved the Work Plan for Supporting Beijing to Deepen the Construction of the Comprehensive Demonstration Zone for Expanding the Opening up of the National Service Industry, supported the construction of a pilot zone for rare disease drug security in Beijing Tianzhu Comprehensive Bonded Zone, and explored new ideas for ensuring the drug use of rare disease patients in China with the goal of improving the safety, effectiveness, and accessibility of drug use by patients. Since the introduction of the policy, the Administrative Committee of the Airport Economic Zone of the Capital Airport, together with the China Rare Disease Alliance, the relevant regulatory authorities and the pharmaceutical trade enterprises in the park, has taken intensive action to complete the first order of rare disease drugs stocking on February 22, 2024, and signed a strategic cooperation agreement with the China Rare Disease Alliance on February 29. On March 16, the first dedicated clinic for rare diseases in Beijing was opened, and by April 11, The world's first drug for treating rare diseases of children with achondroplasia was successfully delivered to patients.

In recent years, the airport economic zone of the Capital Airport has focused on developing the medical and health industry characterized and led by cross-border trade in medicine, continued to improve the level of customs clearance facilitation, innovated and implemented a series of effective measures such as "distribution and centralized reporting, classified supervision, one-time customs clearance and multiple customs declarations", and established a green channel to serve the import inspection of biological products, The efficiency of customs clearance for import and export of goods in the park is 22.08 hours and 0.6 hours higher than the national average respectively. The park gathers more than 30 well-known pharmaceutical enterprises at home and abroad. In 2023, the park will achieve an import and export value of more than 122.8 billion yuan, a year-on-year increase of 41%, of which the scale of pharmaceutical import trade will exceed 100 billion yuan for the first time, accounting for more than 28% of the national total, ranking first in the country.

"Next, the management committee of the airport economic zone of the Capital Airport will work with the main bodies of all sectors of society to further optimize the policy, innovate the practice, and deliver more rare disease drugs to patients, closely centering on the construction of the" rare disease drug security pilot area "." The relevant person in charge of the airport economic zone management committee of the Capital Airport said.

Share to let more people see